Creative Planning’s Theravance Biopharma TBPH Stock Holding History

Creative Planning’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$267K	Buy	16,467 +2,094	+15%	+$37K	﹤0.01%	3510
2025 Q4	$269K	Buy	14,373 +923	+7%	+$15.3K	﹤0.01%	3327
2025 Q3	$196K	Buy	13,450 +842	+7%	+$10.6K	﹤0.01%	3498
2025 Q2	$139K	Buy	+12,608	New	+$123K	﹤0.01%	3356
2025 Q1	–	Sell	-603	Closed	-$5.67K	–	3710
2024 Q4	$5.67K	Buy	+603	New	+$5.49K	﹤0.01%	3406
2017 Q1	–	Sell	-835	Closed	-$27K	–	4901
2016 Q4	$27K	Buy	+835	New	+$25.9K	﹤0.01%	2872
2016 Q3	–	Sell	-1,000	Closed	-$23K	–	4725
2016 Q2	$23K	Hold	1,000	–	–	﹤0.01%	2698
2016 Q1	$19K	Hold	1,000	–	–	﹤0.01%	2799
2015 Q4	$16K	Hold	1,000	–	–	﹤0.01%	2999
2015 Q3	$11K	Buy	+1,000	New	+$12.7K	﹤0.01%	3163
2015 Q2	–	Sell	-1,000	Closed	-$17K	–	2802
2015 Q1	$17K	Buy	+1,000	New	+$18.3K	﹤0.01%	2849
2014 Q4	–	Sell	-114	Closed	-$3K	–	4336
2014 Q3	$3K	Buy	+114	New	+$3.31K	﹤0.01%	3538

Other funds holding TBPH

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ICM

Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Creative Planning's TBPH Position: Q1 2026 in Review

Creative Planning increased its Theravance Biopharma (TBPH) stake by 15% in Q1 2026, buying an estimated $37K and bringing the position to 16,467 shares worth $267K. The position accounts for ﹤0.01% of the portfolio, ranked #3510.

Creative Planning first reported a position in TBPH in Q3 2014 and has held it in 12 quarters since. The position peaked at $269K in Q4 2025. 173 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.

Creative Planning held 16,467 shares of Theravance Biopharma worth $267K as of Q1 2026.
Creative Planning bought 2,094 Theravance Biopharma shares in Q1 2026, an estimated $37K.
Theravance Biopharma made up ﹤0.01% of Creative Planning's portfolio in Q1 2026, its #3510 holding.
Creative Planning first reported a position in Theravance Biopharma in Q3 2014 and has held it in 12 quarters since.
Creative Planning's Theravance Biopharma position peaked at $269K in Q4 2025.
173 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.